Daniel Faga
President, CEO, Director · First Tracks Biotherapeutics, Inc.
- 2026
- Aug 18, 2026
- 10
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Daniel Faga files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- EcoR1 Capital, LLC - $65.00M in TRAX purchases and sales in the last 12 months
- J. Anthony Ware - $1.76M in TRAX purchases and sales in the last 12 months
- John P. Schmid - $1.16M in ANAB purchases and sales in the last 12 months
- Eric J. Loumeau - $1.08M in ANAB purchases and sales in the last 12 months
- Magda Marquet - $531K in ANAB purchases and sales in the last 12 months
- Paul F. Lizzul - $264K in ANAB purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Daniel Faga?
Daniel Faga is a corporate insider, tracked as President, CEO, Director of First Tracks Biotherapeutics, Inc. (TRAX). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Daniel Faga submitted recently?
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Daniel Faga been buying or selling stock?
Recorded transactions: 0 open-market purchases and 12 open-market sales ($2.14M) across all tracked filings.
